Skip to main content

Cyclomydril: Package Insert / Prescribing Info

Package insert / product label
Generic name: cyclopentolate hydrochloride and phenylephrine hydrochloride
Dosage form: ophthalmic solution
Drug class: Mydriatics

Medically reviewed by Drugs.com. Last updated on May 26, 2025.

Cyclomydril Description

CYCLOMYDRIL® (cyclopentolate hydrochloride and phenylephrine hydrochloride ophthalmic solution) is a mydriatic prepared as a sterile topical ophthalmic solution. The active ingredients are represented by the chemical structures:

cyclopentolate hydrochloride

Established Name:
Cyclopentolate Hydrochloride

Chemical Name:
2-(Dimethylamino)ethyl 1 - hydroxy-α-phenylcyclopentaneacetate hydrochloride)

Molecular Formula:
C17H25NO3 • HCl

Molecular Weight:
327.85 g/mol

phenylephrine hydrochloride

Established Name:
Phenylephrine Hydrochloride

Chemical Name:
3-hydroxy-α[(methylamino)-methyl]-, Benzenemethanol, hydrochloride (R)-.

Molecular Formula:
C9H13NO2 • HCl

Molecular Weight:
203.67 g/mol

Each mL of CYCLOMYDRIL® (cyclopentolate hydrochloride and phenylephrine hydrochloride ophthalmic solution) contains:
Active: cyclopentolate hydrochloride 0.2%, phenylephrine hydrochloride 1%. Preservative: benzalkonium chloride 0.01%.
Inactives: edetate disodium, boric acid, hydrochloric acid and /or sodium carbonate (to adjust pH), purified water.

Cyclomydril - Clinical Pharmacology

Cyclopentolate hydrochloride is an anticholinergic drug and phenylephrine hydrochloride is an adrenergic drug. This combination induces mydriasis that is greater than that of either drug alone at its respective concentration. The concentrations of cyclopentolate hydrochloride and phenylephrine hydrochloride have been selected to induce mydriasis with little accompanying cycloplegia. Heavily pigmented irides may require more doses than lightly pigmented irides.

Indications and Usage for Cyclomydril

For the production of mydriasis.

Contraindications

Do not use in patients with hypersensitivity to any component of this preparation.

Warnings

FOR TOPICAL OPHTHALMIC USE ONLY. NOT FOR INJECTION. There have been reports of serious cardiovascular reactions, including ventricular arrhythmias and myocardial infarctions, in patients using higher concentrations of phenylephrine. These episodes, some fatal, have usually occurred in patients with pre-existing cardiovascular diseases. This preparation may cause central nervous system (CNS) disturbances. This is especially true in younger age groups, but may occur at any age, especially with the stronger solutions. Infants are especially prone to CNS and cardiopulmonary side effects from cyclopentolate.

Precautions

General

Caution should be observed when considering use of this medication in the presence of Down's syndrome due to potential increased sensitivity to anticholinergics. This product should be used with caution in patients at risk for angle closure due to the potential to precipitate acute angle closure. Because of the risk of provoking hyperthermia, use with caution in patients, especially children, who may be exposed to elevated environmental temperatures or who are febrile. The use of phenylephrine in the eye may liberate pigment granules from the iris. Mydriatics may produce a transient elevation of intraocular pressure.

Information for Patients

Do not touch dropper tip to any surface, as this may contaminate the solution. Patient should be advised not to drive or engage in hazardous activities while pupils are dilated. Patient may experience sensitivity to light.

Carcinogenesis, Mutagenesis, Impairment of Fertility

There have been no long-term studies done using cyclopentolate hydrochloride and/or phenylephrine hydrochloride in animals to evaluate carcinogenic potential.

Pregnancy

Animal reproduction studies have not been conducted with cyclopentolate hydrochloride and/or phenylephrine hydrochloride. It is also not known whether cyclopentolate hydrochloride and/or phenylephrine hydrochloride can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. CYCLOMYDRIL® (cyclopentolate hydrochloride and phenylephrine hydrochloride ophthalmic solution) should be given to a pregnant woman only if clearly needed.

Nursing Mothers

It is not known whether these drugs are excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when CYCLOMYDRIL® (cyclopentolate hydrochloride and phenylephrine hydrochloride ophthalmic solution) is administered to a nursing woman.

Pediatric Use

Use of cyclopentolate has been associated with psychotic reactions and behavioral disturbances in pediatric patients. Increased susceptibility to cyclopentolate has been reported in infants, young children, and in children with spastic paralysis or brain damage. These disturbances include ataxia, incoherent speech, restlessness, hallucinations, hyperactivity, seizures, disorientation as to time and place. Feeding intolerance may follow ophthalmic use of this product in infants. It is recommended that feeding be withheld after administration, and to observe infants closely for at least 30 minutes (see PRECAUTIONS).

Geriatric Use

No overall differences in safety or effectiveness have been observed between elderly and younger patients.

Adverse Reactions/Side Effects

Ocular

The following ocular adverse experiences have been associated with the use of CYCLOMYDRIL® (cyclopentolate hydrochloride and phenylephrine hydrochloride ophthalmic solution): increased intraocular pressure, burning/irritation upon instillation, photophobia, blurred vision and superficial punctate keratitis.

Nonocular

Use of cyclopentolate hydrochloride has been associated with psychotic reactions and behavioral disturbances in children. These disturbances include ataxia, incoherent speech, restlessness, hallucinations, hyperactivity, seizures, disorientation as to time and place. This drug produces reactions similar to those of other adrenergic and anticholinergic drugs; however, the central nervous system manifestations as noted above are most common. Other manifestations of adrenergic and anticholinergic topical ophthalmic drugs include tachycardia, hyperpyrexia, hypertension, vasodilation, urinary retention, diminished gastrointestinal motility, convulsion, bradycardia, apnea, necrotizing colitis and abdominal distention (in newborns and especially premature infants), skin rash, drowsiness, and decreased secretion in salivary and sweat glands, pharynx, bronchi and nasal passages. Severe manifestations of toxicity include coma, medullary paralysis and death. Systemic toxicity can result from topical application of sympathomimetic drugs: headache, blood pressure elevation, extrasystoles, tachycardia, syncope and cerebrovascular accidents have been reported.

Related/similar drugs

Overdosage

Excessive dosage may produce behavioral disturbances, tachycardia, hyperpyrexia, hypertension, elevated intraocular pressure, vasodilation, urinary retention, diminished gastrointestinal motility and decreased secretion in salivary and sweat glands, pharynx, bronchi and nasal passages. Pulmonary oedema or cardiac arrest may occur due to phenylephrine toxicity. Severe intoxication is characterized by central nervous system depression, coma, circulatory and respiratory failure, and death.
Patients exhibiting signs of overdosage should receive supportive care and monitoring.

Cyclomydril Dosage and Administration

Instill one drop in each eye every five to ten minutes. To minimize systemic absorption, apply pressure over the nasolacrimal sac for two to three minutes following instillation. Observe infants closely for at least 30 minutes.

How is Cyclomydril supplied

CYCLOMYDRIL® (cyclopentolate hydrochloride and phenylephrine hydrochloride ophthalmic solution) is supplied as a sterile solution in 2 mL and 5 mL, in plastic DROP-TAINER® dispensers.

2 mL NDC 0065-0359-02

5 mL NDC 0065-0359-05

Storage: Store at 8°C to 25°C (46°F - 77°F)


Distributed by:
ALCON LABORATORIES, INC.
6201 South Freeway
Fort Worth, Texas 76134-2099

© 2025 Alcon Inc.


Revised: May 2025.

300065206-1223

PRINCIPAL DISPLAY PANEL

NDC 0065-0359-05

Alcon
Cyclomydril®
(cyclopentolate
hydrochloride,
phenylephrine
hydrochloride
ophthalmic
solution)

5 mL Sterile

Rx Only

Sterile Ophthalmic Solution

USUAL DOSAGE: Instill one drop
in each eye every five to ten
minutes. Read enclosed insert.

FOR TOPICAL OPHTHALMIC USE
ONLY

WARNING: Do not touch
dropper tip to any surface as
this may contaminate the
solution.

INGREDIENTS: Each mL
contains: Active:
cyclopentolate hydrochloride
0.2%, phenylephrine
hydrochloride 1%.
Preservative: benzalkonium
chloride 0.01%. Inactives:
edetate disodium, boric acid,
hydrochloric acid and/or
sodium carbonate (to adjust
pH), purified water.

STORAGE: Store at 8°-25° C
(46° to 77° F).

Alcon

ALCON LABORATORIES, INC.
Fort Worth, Texas 76134 USA
Printed in USA

SN:
LOT:
EXP.:
GTIN: 00300650359054


300048632-0821

Carton Label

NDC 0065-0359-05

Alcon
Cyclomydril®
(cyclopentolate
hydrochloride,
phenylephrine
hydrochloride
ophthalmic
solution)

Sterile 5 mL

Rx Only

INGREDIENTS: Each mL contains: Actives: cyclopentolate
hydrochloride 0.2%, phenylephrine hydrochloride 1%.
Preservative: benzalkonium chloride 0.01%. Inactives:
edetate disodium, boric acid, hydrochloric acid and/or
sodium carbonate (to adjust pH), purified water.

WARNING: Do not touch dropper tip to any surface as this
may contaminate the solution.

USUAL DOSAGE: Instill one drop in each eye every five to
ten minutes. Read enclosed insert.

STORAGE: Store at 8°-25° C (46° to 77° F).

Printed in USA

ALCON LABORATORIES, INC.
Fort Worth, Texas 76134 USA

LOT:

EXP.:

300048631-0821

label
CYCLOMYDRIL
cyclopentolate hydrochloride and phenylephrine hydrochloride solution/ drops
Product Information
Product TypeHUMAN PRESCRIPTION DRUGItem Code (Source)NDC:0065-0359
Route of AdministrationOPHTHALMIC
Active Ingredient/Active Moiety
Ingredient NameBasis of StrengthStrength
CYCLOPENTOLATE HYDROCHLORIDE (UNII: 736I6971TE) (CYCLOPENTOLATE - UNII:I76F4SHP7J) CYCLOPENTOLATE HYDROCHLORIDE2 mg in 1 mL
PHENYLEPHRINE HYDROCHLORIDE (UNII: 04JA59TNSJ) (PHENYLEPHRINE - UNII:1WS297W6MV) PHENYLEPHRINE HYDROCHLORIDE10 mg in 1 mL
Inactive Ingredients
Ingredient NameStrength
BENZALKONIUM CHLORIDE (UNII: F5UM2KM3W7)
EDETATE DISODIUM (UNII: 7FLD91C86K)
BORIC ACID (UNII: R57ZHV85D4)
HYDROCHLORIC ACID (UNII: QTT17582CB)
SODIUM CARBONATE (UNII: 45P3261C7T)
WATER (UNII: 059QF0KO0R)
Packaging
#Item CodePackage DescriptionMarketing Start DateMarketing End Date
1NDC:0065-0359-022 mL in 1 BOTTLE, PLASTIC; Type 0: Not a Combination Product06/30/1958
2NDC:0065-0359-055 mL in 1 BOTTLE, PLASTIC; Type 0: Not a Combination Product06/30/1958
Marketing Information
Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
ANDAANDA08430006/30/1958
Labeler - Alcon Laboratories, Inc. (008018525)
Establishment
NameAddressID/FEIBusiness Operations
Alcon Research LLC007672236manufacture(0065-0359)

More about Cyclomydril (cyclopentolate / phenylephrine ophthalmic)

Patient resources

Related treatment guides